(Q38007308)

English

A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression

scientific article published on 27 April 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 August 2017

0 references

A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression (English)

1 reference

Europe PubMed Central

26 August 2017

meta-regression

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

object named as

Ann-Lii Cheng

5

0 references

author name string

Ying-Chun Shen

1

1 reference

Europe PubMed Central

26 August 2017

Chiun Hsu

2

1 reference

Europe PubMed Central

26 August 2017

Chia-Chi Cheng

3

1 reference

Europe PubMed Central

26 August 2017

Fu-Chang Hu

4

1 reference

Europe PubMed Central

26 August 2017

publication date

27 April 2012

1 reference

Europe PubMed Central

26 August 2017

1 reference

Europe PubMed Central

26 August 2017

82

1 reference

Europe PubMed Central

26 August 2017

5

1 reference

Europe PubMed Central

26 August 2017

275-289

1 reference

Europe PubMed Central

26 August 2017

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Risks of transfusion-transmitted infections: 2003.

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach.

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Treatment of hepatitis C: critical appraisal of the evidence.

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis.

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Covariate heterogeneity in meta-analysis: criteria for deciding between meta-regression and individual patient data

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Understanding heterogeneity in meta-analysis: the role of meta-regression

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors.

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Recommendations for the assessment of progression in randomised cancer treatment trials

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Natural history of chronic hepatitis B virus infection and long-term outcome under treatment

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000337293

21 January 2018

Identifiers

10.1159/000337293

1 reference

Europe PubMed Central

26 August 2017

1 reference

Europe PubMed Central

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38007308&oldid=2096261142"